A study to evaluate the safety of rapid and conventional rituximab infusion in a tertiary care centre

M. Janardhanan, V. Nayak, J. Thomas, K. L. Bairy

Research output: Contribution to journalArticle

Abstract

Antibody-based therapy, in particular rituximab, is a promising strategy in the treatment of Non-Hodgkin lymphoma. Rituximab chemotherapy combinations have revolutionised the treatment outcomes in NHL. A major barrier to effective treatment of rituximab is the lengthy infusion time. Hence, by reducing the chair time of one patient from the conventional 4-6 hours to rapid (90 minutes) infusion, more number of patients can be accommodated in outpatient facility. A total of 40 patients who received rapid infusion of rituximab over 90 minutes and 30 patients who received conventional infusion were evaluated for the safety parameter. It was observed that rapid infusion was well tolerated with no grade 3 or 4 reaction and there was no significant difference in the safety analysis between the rapid and conventional infusion. Therefore, it can be concluded that rapid infusion of rituximab can be opted as a safer alternative to conventional infusion and also improves patient satisfaction.

Original languageEnglish
Pages (from-to)237-242
Number of pages6
JournalInternational Journal of Toxicological and Pharmacological Research
Volume8
Issue number4
Publication statusPublished - 01-08-2016

Fingerprint

Tertiary Care Centers
Safety
Combination Drug Therapy
Patient Satisfaction
Non-Hodgkin's Lymphoma
Outpatients
Therapeutics
Rituximab
Antibodies

All Science Journal Classification (ASJC) codes

  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

@article{605aa08ff85c4a78985c5102538878ed,
title = "A study to evaluate the safety of rapid and conventional rituximab infusion in a tertiary care centre",
abstract = "Antibody-based therapy, in particular rituximab, is a promising strategy in the treatment of Non-Hodgkin lymphoma. Rituximab chemotherapy combinations have revolutionised the treatment outcomes in NHL. A major barrier to effective treatment of rituximab is the lengthy infusion time. Hence, by reducing the chair time of one patient from the conventional 4-6 hours to rapid (90 minutes) infusion, more number of patients can be accommodated in outpatient facility. A total of 40 patients who received rapid infusion of rituximab over 90 minutes and 30 patients who received conventional infusion were evaluated for the safety parameter. It was observed that rapid infusion was well tolerated with no grade 3 or 4 reaction and there was no significant difference in the safety analysis between the rapid and conventional infusion. Therefore, it can be concluded that rapid infusion of rituximab can be opted as a safer alternative to conventional infusion and also improves patient satisfaction.",
author = "M. Janardhanan and V. Nayak and J. Thomas and Bairy, {K. L.}",
year = "2016",
month = "8",
day = "1",
language = "English",
volume = "8",
pages = "237--242",
journal = "International Journal of Toxicological and Pharmacological Research",
issn = "0975-5160",
publisher = "International Journal of Toxicological and Pharmacological Research",
number = "4",

}

A study to evaluate the safety of rapid and conventional rituximab infusion in a tertiary care centre. / Janardhanan, M.; Nayak, V.; Thomas, J.; Bairy, K. L.

In: International Journal of Toxicological and Pharmacological Research, Vol. 8, No. 4, 01.08.2016, p. 237-242.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A study to evaluate the safety of rapid and conventional rituximab infusion in a tertiary care centre

AU - Janardhanan, M.

AU - Nayak, V.

AU - Thomas, J.

AU - Bairy, K. L.

PY - 2016/8/1

Y1 - 2016/8/1

N2 - Antibody-based therapy, in particular rituximab, is a promising strategy in the treatment of Non-Hodgkin lymphoma. Rituximab chemotherapy combinations have revolutionised the treatment outcomes in NHL. A major barrier to effective treatment of rituximab is the lengthy infusion time. Hence, by reducing the chair time of one patient from the conventional 4-6 hours to rapid (90 minutes) infusion, more number of patients can be accommodated in outpatient facility. A total of 40 patients who received rapid infusion of rituximab over 90 minutes and 30 patients who received conventional infusion were evaluated for the safety parameter. It was observed that rapid infusion was well tolerated with no grade 3 or 4 reaction and there was no significant difference in the safety analysis between the rapid and conventional infusion. Therefore, it can be concluded that rapid infusion of rituximab can be opted as a safer alternative to conventional infusion and also improves patient satisfaction.

AB - Antibody-based therapy, in particular rituximab, is a promising strategy in the treatment of Non-Hodgkin lymphoma. Rituximab chemotherapy combinations have revolutionised the treatment outcomes in NHL. A major barrier to effective treatment of rituximab is the lengthy infusion time. Hence, by reducing the chair time of one patient from the conventional 4-6 hours to rapid (90 minutes) infusion, more number of patients can be accommodated in outpatient facility. A total of 40 patients who received rapid infusion of rituximab over 90 minutes and 30 patients who received conventional infusion were evaluated for the safety parameter. It was observed that rapid infusion was well tolerated with no grade 3 or 4 reaction and there was no significant difference in the safety analysis between the rapid and conventional infusion. Therefore, it can be concluded that rapid infusion of rituximab can be opted as a safer alternative to conventional infusion and also improves patient satisfaction.

UR - http://www.scopus.com/inward/record.url?scp=84981313242&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84981313242&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:84981313242

VL - 8

SP - 237

EP - 242

JO - International Journal of Toxicological and Pharmacological Research

JF - International Journal of Toxicological and Pharmacological Research

SN - 0975-5160

IS - 4

ER -